Navarro, Natalia http://orcid.org/0000-0002-2160-6656
Molist, Carla
Sansa-Girona, Júlia
Zarzosa, Patricia
Gallo-Oller, Gabriel
Pons, Guillem
Magdaleno, Ainara
Guillén, Gabriela
Hladun, Raquel
Garrido, Marta
Segura, Miguel F.
Hontecillas-Prieto, Lourdes
de Álava, Enrique
Ponsati, Berta
Fernández-Carneado, Jimena
Almazán-Moga, Ana
Vallès-Miret, Mariona
Farrera-Sinfreu, Josep
de Toledo, Josep Sánchez
Moreno, Lucas
Gallego, Soledad
Roma, Josep http://orcid.org/0000-0001-7692-6123
Funding for this research was provided by:
Instituto de Salud Carlos III (PI18/00398, FI18/00178)
ACCIÓ (COMRDI15-1-0014)
Article History
Received: 13 January 2022
Revised: 13 July 2022
Accepted: 11 September 2022
First Online: 11 October 2022
Declarations
:
: RA08 is under patent protection PCT/EP2020/083987 (owned by BCN PEPTIDES, S.A.): “Peptides for the treatment of cancer and/or metastasis”. Dr. Moreno is member of a data monitoring committees for clinical trials sponsored by Novartis, Actuate Therapeutics, Shionogi, Incyte, the University of Southampton and the Royal Marsden NHS Foundation Trust, and had a consulting role for Novartis and Shionogi (no direct compensation). Dr. Moreno is member of the Executive Committee of SIOPEN (European neuroblastoma research cooperative group) which receives royalties for the sales of dinutuximab beta. The remaining authors declare that they have no conflict of interest. VHIR receives funding from sponsors for DMC participation, advisory role or conducting industry-sponsored clinical trials.
: All the animal procedures were approved by the Ethics Committee of Animal Experimentation of the Vall d’Hebron Research Institute (CEEA) and were in line with EU directive 2010/63/EU.